The impact of embolization endpoints on the efficacy of uterine artery embolization for adenomyosis.

IF 2 4区医学 Q2 SURGERY

Minimally Invasive Therapy & Allied Technologies Pub Date : 2025-10-01 Epub Date: 2025-07-17 DOI:10.1080/13645706.2025.2531204

Liang Yin, Xingwei Sun, Meijin Wu, Mingqing Zhang, Jian Jing, Xuming Bai, Yong Jin

{"title":"The impact of embolization endpoints on the efficacy of uterine artery embolization for adenomyosis.","authors":"Liang Yin, Xingwei Sun, Meijin Wu, Mingqing Zhang, Jian Jing, Xuming Bai, Yong Jin","doi":"10.1080/13645706.2025.2531204","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to assess how embolization endpoints affect the efficacy of uterine artery embolization (UAE) for adenomyosis.Methods: In this single-center retrospective cohort study, patients treated with UAE from 2014-2018 received the standard embolization endpoint (SEE), while those from 2019-2022 received the delayed embolization endpoint (DEE). Clinical outcomes, including embolic microsphere volume, uterine volume, CA125 levels, hemoglobin, menstrual flow, dysmenorrhea, and postoperative complications, were compared between the groups.Results: At six months post-procedure, all patients showed significant improvement in clinical indicators (p < 0.01). Group DEE used significantly more embolic microspheres than Group SEE (p < 0.01) and achieved greater reductions in CA125, menstrual volume, and dysmenorrhea (p < 0.05). There were no significant differences in postoperative uterine volume, hemoglobin, or complication rates between the groups (p > 0.05).Conclusions: UAE is a safe and effective treatment for adenomyosis. Compared to the standard approach, the delayed embolization endpoint provides superior symptom relief and warrants broader clinical adoption.","PeriodicalId":18537,"journal":{"name":"Minimally Invasive Therapy & Allied Technologies","volume":" ","pages":"406-415"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minimally Invasive Therapy & Allied Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13645706.2025.2531204","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to assess how embolization endpoints affect the efficacy of uterine artery embolization (UAE) for adenomyosis.

Methods: In this single-center retrospective cohort study, patients treated with UAE from 2014-2018 received the standard embolization endpoint (SEE), while those from 2019-2022 received the delayed embolization endpoint (DEE). Clinical outcomes, including embolic microsphere volume, uterine volume, CA125 levels, hemoglobin, menstrual flow, dysmenorrhea, and postoperative complications, were compared between the groups.

Results: At six months post-procedure, all patients showed significant improvement in clinical indicators (p < 0.01). Group DEE used significantly more embolic microspheres than Group SEE (p < 0.01) and achieved greater reductions in CA125, menstrual volume, and dysmenorrhea (p < 0.05). There were no significant differences in postoperative uterine volume, hemoglobin, or complication rates between the groups (p > 0.05).

Conclusions: UAE is a safe and effective treatment for adenomyosis. Compared to the standard approach, the delayed embolization endpoint provides superior symptom relief and warrants broader clinical adoption.

查看原文本刊更多论文

栓塞终点对子宫动脉栓塞治疗bb0疗效的影响。

背景：本研究旨在评估栓塞终点如何影响子宫动脉栓塞（UAE）治疗子宫腺肌症的疗效。方法：在这项单中心回顾性队列研究中，2014-2018年接受UAE治疗的患者接受标准栓塞终点（SEE），而2019-2022年接受延迟栓塞终点（DEE）。比较两组患者的临床结果，包括栓塞微球体积、子宫体积、CA125水平、血红蛋白、月经流量、痛经、术后并发症。结果：术后6个月，所有患者的临床指标均有显著改善（p < 0.05）。结论：UAE是一种安全有效的治疗子宫腺肌症的方法。与标准方法相比，延迟栓塞终点提供了更好的症状缓解，值得更广泛的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minimally Invasive Therapy & Allied Technologies 医学-外科

CiteScore

3.80

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Minimally Invasive Therapy and Allied Technologies (MITAT) is an international forum for endoscopic surgeons, interventional radiologists and industrial instrument manufacturers. It is the official journal of the Society for Medical Innovation and Technology (SMIT) whose membership includes representatives from a broad spectrum of medical specialities, instrument manufacturing and research. The journal brings the latest developments and innovations in minimally invasive therapy to its readers. What makes Minimally Invasive Therapy and Allied Technologies unique is that we publish one or two special issues each year, which are devoted to a specific theme. Key topics covered by the journal include: interventional radiology, endoscopic surgery, imaging technology, manipulators and robotics for surgery and education and training for MIS.